Calcitonin gene-related peptide monoclonal antibody
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
This article is a stub. |
Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.[1][2]
Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.[2][3]
Drugs[edit | edit source]
Currently FDA-licensed CGRP mAbs are:
- Eptinezumab (Vyepti), approved in 2020
- Erenumab (Aimovig), approved in 2018
- Fremanezumab (Ajovy), approved in 2018
- Galcanezumab (Emgality), approved in 2018[2]
News and articles[edit | edit source]
- 2020, Can migraines be untangled by new medical thinking? - The Observer
Learn more[edit | edit source]
- Calcitonin gene-related peptide monoclonal antibodies - The Migraine Trust